Tumours of the pituitary gland: six cases by Critchley, Julian Arthur John Hall
TUMOURS OF THE PITUITARY GLAND - SIX
CASES
INTRODUCTION
The theme of this dissertation is the mode of presentation,
assessment and management of six patients with tumours of the
pituitary gland. Such tumours may be secretory or non-secretory.
Typically secretory tumours present with endocrine abnormalities
due to hypersecretion of a particular hormone, while non-
secretory tumours present with symptoms caused by the expansion
of the lesion in the pituitary fossa, such as headaches, visual
field defects or hypopituitarism. Treatment is by surgery if
there are signs of visual impairment due to optic nerve
compression or if there is internal hydrocephalus. Otherwise
radiotherapy is normally the method of choice. Careful assessment
of pituitary function is necessary and treatment itself may
increase the impairment, compounding the necessity for replacement
therapy. However recently the management of certain of the
secretory tumours has been modified by the introduction of the
drug Bromocryptine.
Of the six cases presented two have secretory tumours and are
discussed in detail. The other four have non-secretory tumhurs and
illustrate various modes of presentation, and resulting endocrine
deficiences. The assessment of pituitary function is considered
in relation to these cases and finally some aspects of the insulin
hypoglycaemia test are examined in depth.
CASE I - MR ALEXANDER COOK
HIESENTATION
Alexander Cook is a thirty eight year old single man who
works on a Norwegian Oil Rig and lives with his parents when on
leave. He had no previous medical history when he first presented
with recurrent frontal headaches of increasing severity. These
irere not associated with any visual disturbances but he was aware
of an increase in his shoe and glove sizes and in the tightness of
a ring which he had worn for many years.
He denied that there had been a change in his facial appear¬
ance and was unable to produce any suitable photographs for
comparison. However the prominence of his jaw was striking which
together with his history was highly suggestive of acromegaly.
General physical examination revealed no other abnormalities
and he was normo-tensive with a normal male distribution of body
hair and had no detectable visual impairment.
INVESTIGATIONS
The clinical diagnosis of acromegaly was supported by per¬
forming an oral glucose tolerance test in which his elevated basal
levels of growth hormone were not suppressed by the administration
of glucose. However, his glucose tolerance was normal.
Assessment of his visual fields by perimetry revealed no
defects but a skull x-ray combined with tomography of the pituitary
fossa demonstrated downwards expansion of the sella on the left
hand side without any bony erosion suggestive of superior extension
of the lesion. Increased thickness of the soft tissues of his
hands was shorn by x-ray.
Although he had no clinical signs or symptoms indicative of
deficiency or hypersecretion of other pituitary hormones, basic
screening was performed. Thyroid function, as assessed by protein
bound iodine, T8 resin uptake and free thyroxine index was normal.
Twenty four hour.:, urinary outputs of 17- hydroxycortiiCBteroids,
Follicle Stimulating Hormone and Intestitial Cell Stimulating
Hormone were all normal.
MANAGEMENT
In view of the absence of any signs of optic chiasmal
compression the decision was made to treat him with radiotheraphy
rather than surgery. However, at that time, there were current
reports of the successful lowering of Growth Hormone in
acromegalics by Bromocryptine (C.B. 154) and it was decided to
assess the value of this drug prior to using radiotherapy. Before
its commencement and at monthly intervals during Bromocryptine
treatment he was assessed by means of sequential measurements of
hand volume and skin thickness as well as his growth hormone
response in a two-hour glucose tolerance test. The dose of
bromocryptine was initially 2.5 mg every six hours and was increased in
monthly increments to 40 mg daily.
He showed a definite response to this drug with regard to his
growth hormone levels although the basal levels remained above
normal and were not supressed by glucose administration. Despite
this good response he was given conventional high voltage radio¬
therapy in November 1976 and was thereafter maintained on
Bromocryptine (40 mg daily).
SUBSEQUENT COURSE AND INVESTIGATIONS
After the course of radiotheraphy he began to complain again
of lassitude, increasing tiredness, frequent headaches and epi¬
gastric discomfort and was re-admitted to the Metabolic Unit of
the Western General Hospital for full assessment of his pituitary
function.
Preliminary investigations including a full blood count,
erythocyte sedimentation rate, urea and electrolyte, liver function
tests and lying and standing blood pressure were all within normal
limits. Screening tests for thyroid function and twenty four hour
urinary gonadotrophin levels were also normal. However his plasma
Cortisol levels were low and showed a loss of diurnal variation.
In order to determine his functional pituitary reserve^ an
insulin hypoglycaemia test was performed and <c<0n^ined with
administration of thyrotrophin releasing hormone (TRIl).
Satisfactory hypoglycaemia was achieved with spontaneous return
to normoglycaemia and his plasma Cortisol levels rose
satisfactorily. Basal growth hormone levels were still elevated
but showed a normal pattern of response to insulin. TRH -
stimulated TSII release reached normal levels but the response
was delayed.
He was discharged home on a lower dose of Bromocryptine
(10 mg daily) but was re-admitted at the request of his general
practitioner three weeks later with increasing lassitude and
postural hypotension. Further investigations included x—rays of
his skull, re-assessment of his visual fields by perimetry and a
short Synacthen test to exclude primary adrenal cortical deficiency.
However these investigations were normal and he had an excellent
response to synacthen, reflected by a good post-Synacthen rise
in plasma Cortisol and a twofold rise in his urinary 17- hydro-
xycorticosteroid output. There was a slight improvement in the
diurnal pattern of his plasma Cortisol levels and in the absence
of abnormal findings he was discharged home. When reviewed three
months later he was feeling extremely well and had 110 further
evidence of deficient pituitary function although his basal growth
hormone level vras still slightly elevated and was not suppressed
by administration of oral glucose.
DISCUSSION OF CASE I
Acromegaly usually results from the presence of a growth
hormone secreting pituitary adenoma of eosinophil or mixed cell
type. In an adult whose epiphyses have fused it leads to an over
growth of all organs, skin, soft tissues and skeleton.
Local expansion of the tumour may cause features common to
all pituitary tumours, such as headache which is attributed
either to dural traction, or to raised intracranial pressure if
there is obstruction to the circulation of cerebrospinal fluid.
Visual defects due to chiasmal compression may develop with
variable loss of vision in the temporal fields and these may be
asymetrical. Loss of visual acuity and colour vision with optic
atrophy may also result if compression is more severe and long
standing. Compression or destruction of normal pituitary tissue,
the hypothalamus or pituitary stalk may result in deficient
secretion of other pituitary hormones and usually affects the
gonadotrophins first. However hypogonadism may result from
elevated prolactin levels due either to its secretion by tumour
cells or to pituitary stalk compression with impaired release of
prolactin-inhibitory factor. This is discussed in more detail in
relation to Case II.
In addition to these features common to all types of
pituitary tumour, acromegaly is associated with certain specific
complications apart from its effects on skin and bone. Due to
the anti-insulin effects of growth hormone, basal levels of
insulin are raised and eventually pancreaticcell exhaustion
may occur resulting in an impairment of glucose tolerance and
diabetes mellitus. There is a tendency for hypertension to
develop in acromegalics and although the cause of this is unclear
it is notably resistant to conventional anti-hypertensive therapy
and may be severe. In addition, an unusual type of cardio¬
myopathy may develop which, in combination with the risks of
diabetes raellitus and hypertension, leads to an increased
incidence of early death from cardiovascular complications. It
has been estimated that untreated acromegalics have approximately
twice the normal mortality rate of their age group, mainly as a
result of these complications. (Wright et al, 1970). Contributing
to the morbidity rather than the mortality from acromegaly is the
tendency for the early onset of osteoarthritis to occur, probably
due to skeletal deformities.
For the reasons outlined above, early treatment is mandatory
and in the past the choice was between surgery and radiotheraphy.
Surgery is indicated for those cases with chiasmal compression
and visual field defects and often post operative radiotheraphy
is required when growth hormone levels are not reduced to normal.
Hypopituitarism or diabetes insipidus may follow surgery.
Irradi ation in cases without visual field defects carries less
chance of causing hypopituitarism but the full effects of either
treatment may not be evident for three to four years. (Kanis et
al, 1974)
The use of Bromocryptine in acromegaly was suggested after
it had been observed that acromegalic patients had a paradoxical
response to dopamine agonists. They show a fall in growth hormone
levels (Liuzzi et al, 1972), instead of the usual rise. Bromo-
cryptine is a dopamine agonist and well established in the treat¬
ment of hyperprolactinaemia. (Besser et al, 1972) It has been
shown to reduce growth hormone levels in acromegalics (Thorner et
al, 1975a) although, as this case illustrates^they rarely fall to
the normal range. Bromocryptine's place in the management of
acromegaly is at present undefined but it may provide an extremely
useful adjunct to conventional therapy. It does have the added
advantage of improving the hypogonadism and impotence which results
from any coincidental elevation in prolactin levels.
CASE II - MISS DIANE GRAHAM
PRESENTATION
Diane Graham is a twenty five year old unmarried clerkess, who
presented at the age of twenty (1972) with primary araenorrhoea.
She was of average height and build with well developed secondary
sexual characteristics, normal pubic and axillary hair and no signs
of hirsuitism. However from the age of fifteen she had been
troubled by a spontaneous discharge of milky white fluid from both
nipples. Questioning revealed that she suffered from recurrent
headaches but had no associated visual symptoms.
PRELIMINARY INVESTIGATIONS
Chromosomnal analysis confirmed that she had the normal female
46 XX configuration. Her visual fields and sense of smell were
normal and no pituitary lesion was revealed by x-ray. Gynaeco¬
logical examination was performed under general anaesthesia and one
ovary biopsied. Her external and internal genitalia were of normal
appearance although the uterus and ovaries were small. However,
the ovarian tissue contained numerous primondial follicles which
suggested a lack of gonadotrophin stimulation.
Plasma assays of gonadotrophins and sex steroids were not
locally available in 1972 and thus the investigation of her hormonal
status was based on their urinary excretion. Her twenty four hour
outputs of oestrogens and pregnanedio.l were well below the normal
range for a non-pregnant woman of reproductive age as was her
excretion of luteinising hormone. There was, of course, no evidence
of impaired renal function and her thyroid function and cortico¬
steroid excretion were normal.
These results suggested hypopituitary hypogonadism and the
induction of ovulation was attempted using clomipliene although she
had no desire to become pregnant at that time. This drug is
thought to act at hypothalamic level by blocking oestrogen
receptors and thus induces a rise in FSII and LH levels by inter¬
fering with the negative feed back control mechanism. As well as
promoting ovulation, it is a test of the integrity of the hypo-
thalam:o — pituitary ovarian axis. Diane responded with an
excellent rise in her output of total urinary oestrogens, but
there was no rise in pregnanediol. She did not menstruate and
ti&d. no evidence of ovulation or corpus luteum formation. Several
further courses of clomiphene failed to induce menstruation or
ovulation and she decided not to continue treatment with this drug.
FURTHER INVESTIGATIONS
In 1976, advances in knowledge had enabled her situation to
be reassessed. The combination of amenorrhoea, galactorrhoea, low
oestrogen levels and lack of response to clomiphene was very
suggestive of hyperprolactinaemic hypogonadism which was confirmed
when her prolactin level was shown to be very high.
When her skull x-ray was repeated, she was found to have an
enlarged pituitary fossa in which tomograms defined a space-
occupying lesion on the left side. There was expansion of the
fossa and erosion of the dorsum sella and posterior clinoid process
on the left, which suggested upward extension of the lesion. How¬
ever no defect was detected on repeating the assessment of her
visual fields.
In the light of these findings, her pituitary function was re¬
examined. Thyroid function as assessed by FBI, Tr, resin uptake, 4-
o
hour radio iodine uptake and a TRII stimulation test was normal.
She had a normal response to insulin with spontaneous reversion to
normoglycaemia following hypoglycaemia and normal rises in plasma
Cortisol and growth hormone levels. Administration of gonado¬
tropin releasing hormone (LIIRIl) produced an entirely normal
gonadotrophin response, confirming that her hypogonadism was
secondary to hyperprolactinaemia rather than to deficiency of
pituitary gonadotrophins.
FURTHER MANAGEMENT
The decision was taken to treat her surgically but in the
interim she was commenced on bromocryptine. She responded to this
with a partial lowering of her prolactin levels and cessation of
galactorrhoea. At operation the tumour was removed and histology
showed it to be an eosinophilic adenoma. Surgery presented a
particular problem in her case as she was a Jehovah Witness and
would not give her permission to have blood transfusion even if
the situation became critical. Fortunately this complication
did not arise. She was discharged home on a maintenance dose of
prednisolone which had been commenced, as is routine, at the time
of surgery.
POST OPERATIVE ASSESSMENT
She was admitted to the Metabolic Unit three months post
operatively for withdrawal of steroids and assessment of pituitary
function. Her blood pressure remained steady and her blood count,
electrolyte levels and urinary corticosteroid excretion were also
normal. Her plasma Cortisol levels were low, but exhibited diurnal
variation. Thyroid function tests were normal. A combined
pituitary function test was performed after an overnight fast with
administration of insulin, TRII and LHHH. The responses to these
three hormones were all normal. However, her prolactin level was
still considerably elevated and she was recommenced on Bromo-
cryptine (40 mgr per day).
DISCUSSION
There are two possible mechanisms whereby a tumour in the
region of the hypophysis may cause hyperprolactinaemia. Firstly,
as in the case of Diane Graham, there may be a prolactin-secreting
tumour actually present within the pituitary gland. This may be
primarily composed of eosinophilic cells or may be of mixed or
chromophobe cell origin (Friesen et al, 1972). The tumours are
often very small initially and in this case the onset of the
galactorrhoea preceded the appearance of radiological changes in
the pituitary fossa by nine years.
The other situation in which hyperprolactinaemia may be
associated with a pituitary or hypothalamic tumour is if there is
compression of the pituitary stalk or cells producing prolactin
inhibitory factor (Turkington, 1972). Unlike other anterior
pituitary hormones, prolactin is under predominantly inhibitory
control from the hypothalamus and thus interruption of the
hypothalamo-pituitary connections results in hypersecretion of
prolactin with hyposecretion of the other hormones.
In the absence of associated gonadotrophin deficiency,
elevated prolactin levels cause amenorrhoea by inhibiting the
ovarian response to gonadotrophins. Thus oestrogen levels are
low and there is an impaired response to cloraiphene administration
(Jacobs et al, 1976). Bromocryptine has been shown to be very
effective at lowering prolactin levels with cessation of
galactorrhoea and resumption of ovulation and menstruation.
(Thorner et al, 1975b)
In the case of a proven pituitary tumour, Bromocryptine will
lower prolactin levels but surgery is usually required when there
are signs of chiasmal compression. If the patient is a woman who
may wish to become pregnant, surgery or radiotherapy should be
performed even in the absence of chiasmal compression as the rapid
enlargement of the pituitary during pregnancy may cause a rapid
deterioration in vision. (Jacobs and Franks, 1975)
In the absence of subsequent development of hypopituitarism,
Diane Graham has a good chance of retaining normal ovarian function
and fertility while on Br omocryptine therapy.
CASE III - MISS MARION STARK.
PRESENTATION
Marion Stark is a fifty-five year old spinster who presented
to an ophthalmologist on account of a progressive decrease in her
visual acuity over the previous three years. Examination of her
optic fundi revealed temporal pallor of both optic discs and she
had a bilateral upper temporal quadrant visual field defect which
was confirmed on perimetry. Enlargement of the pituitary fossa
was demonstrated by a skull x-ray.
Her general health was good and she had no other symptoms or
signs suggestive of endocrine disease. At that time she was fifty
four years old and menstruation had ceased spontaneously ten years
earlier,
A right frontal craniotomy was performed on 20th July, 1976
and a pituitary tumour removed. It was compressing the optic
chiasma and on histological examination it was found to be a
chromophobe adenoma. She was discharged on the maintenance dose
of corticosteroids which had been begun, as is routine^to cover
her pituitary operation.
POST OPERATIVE ASSESSMENT
Four months after this operation she was admitted to the
Western General Hospital for the withdrawal of her steroid therapy
and assessment of her pituitary function. She had no complaints
■pther than being aware of impaired vision in the left upper
temporal field which was confirmed clinically.
Her blood pressure, urine and routine haematology and bio¬
chemistry were all within normal limits as were the results of
screening tests for thyroid function. However, her twenty four
hour radio iodine uptake was at the lower limit of normal and her
plasma Cortisol levels were low, although they did show a little
diurnal variation.
A combined pituitary function test was performed with the
standard doses of insulin (0.1 mg/kg), TRII (200 rng) and LIIUH
(50 mg). Hypoglycaemia was achieved but lier blood glucose rose
slowly and after ninety minutes was only 303 rnmol/l. Her basal
plasma Cortisol levels were in this instance unrecordable but
they rose satisfactorily after the insulin. Iler growth hormone
also rose from an unrecordable basal level, but the response was
sluggish and subnormal. Her TSH response to T11H was similarly
delayed and basal levels of LH and FSH were very low for a woman
of post menopausal age with a minimal response to LHRH. She had
an elevated serum prolactin concentration.
■DISCUSSION
These results indicated that she had a degree of impairment
of hypothalamopituitary function but, despite low basal levels of
plasma Cortisol and growth hormone, was able to respond to the
stress of insulin - induced hypoglycaemia. It was decided not to
recommence her steroid therapy but to review her at regular
intervals. Her low gonadotrophin levels and raised prolactin level
would not require treatment as she was post menopausal and in the
absence of significant ovarian oestrogen production she is un¬
likely to develop galactorrlioea.
CASE IV - ANDREW CRISP
PRESENTATION
Andrew Crisp is a, fifteen year old schoolboy, who presented
with a history of intermittent visual impairment over the
preceding three months. He had experienced headaches but these
were not severe and he had no other symptoms.
He was a plump, highly intelligent boy but wr'as . well below
the average height for his age and was prepubertal. Visual acuity
was considerably impaired in both eyes and worse on the left with
a pallor of the left optic disc suggestive of optic atrophy.
Assessment of his visual fields by perimetry demonstrated the
presence of a bitemporal hemianopia and very marked constriction
of the left visual field.
Considerable expansion of the pituitary fossa was seen on the
skull x-ray. An EMI scan confirmed the presence of a well defined
lesion in the suprasellar region with some expansion of both
lateral ventricles and the third ventricle, which was indicative
of internal hydrocexDhalus.
MANAGEMENT
On 28th June 1976 a chromophobe adenoma of the pituitary
gland was removed at operation. It was obliterating the cisterna
chiasmatica and had compressed both optic nerves from below. He
was given the normal steroid cover during and after surgery and
post operatively developed diabetes insipidus which required
therapy with symtopressin.
POST OPERATIVE ASSESSMENT
Four months later he was admitted to the Western General
Hospital for withdrawal of both steroids and Syntopressin com¬
bined with assessment of his pituitary fmiction.
He complained of having had little improvement in the vision
of his left eye, but that on the right side had improved. The
left visual field was still markedly constricted. He had not
altered in height and T/as still prepubertal.
In the ward he remained normo tensive and routine
haematology and biochemistry were normal. Screening tests for
thyroid function including radio iodine uptake studies were
within the normal range but his diurnal plasma Cortisol levels
were all unrecordable, which suggested ACTII deficiency.
During the course of an insulin hypoglycaemia test he
experienced a profound and prolonged fall in blood sugar. This
was associated with no detectable rise in either plasma Cortisol
or growth hormone from their unrecordable levels. His TSII response
to TEH was normal but his gonadotrophin levels were low and failed
to respond to LHRH. He had a considerably elevated serum prolactin
concentration.
DISCUSSION
These investigations confirmed that he had a combined
pituitary deficiency of ACTII, growth hormone and gonadotropins,
although TSII secretion was adequate. The very high prolactin
level suggests that there is damage to the hypothalamus or pituitary
stalk although failure to respond to LHRH indicates that there mustaiso
be damage to the pituitary cells themselves.
He was then recommenced on maintenance steroid therapy.
Ultimately he will require induction of puberty with IICG and he
will never achieve his expected height. It is also unlikely that
he will regain the vision in his left eye. The clinical implication
of his raised prolactin level is uncertain.
CASE V MRS ELIZABETH AITKEN
PRESENTATION
Mrs Aitken originally presented at the age of thirty two,
sixteen months after the birth of her first child, with lethargy,
anorexia and vague headaches. She had not resumed menstruation
but no details have been recorded about her lactation history.
Examination of her visual fields had demonstrated bilateral upper
temporal field defects but x-ray of her pituitary fossa was
normal. However, an EMI scan outlined a cystic lesion in the
region of the hypophysis. A combined pituitary function test done
at that time confirmed the clinical diagnosis of hypopituitarism.
A right frontal craniotomy was performed and a large supra¬
sellar cyst aspirated. Post operatively she developed diabetes
insipidus,requiring pitressin therapy.
SUBSEQUENT ASSESSMENT
Six months later she was admitted to the Metabolic Unit in
March 1975 for further assessment. She was on maintenance doses
of cortisone, thyroxine and using DDAVP twice daily. The latter
is a synthetic analogue of vasopressin which is administered intra-
nasallyarid acts for longer than the older preparations such as
Pitressin tannate iix-oil and Syntopressin.
Her complaints on admission were persisting secondary
amenorrhoea and loss of libido. She had no galactorrlioea and on
examination, apart from scanty pubic and axillary hair, there were
no physical abnormalities. Her visual fields were undiminished
when tested by confrontation and her optic fundi were normal.
All the above three drugs were stopped on admission,in
preparation for pituitary function assessment. Her plasma Cortisol
levels were low and did not show diurnal variation. Following the
administration of insulin, LHRII and TRH, she had a normal hypo-
glycaemic response with a spontaneous return to euglycaemia
although her Cortisol levels remained unrecordable throughout the
test. However, she had a definite, although subnormal growth
hormone response. Her subnormal gonadotrophin levels were un¬
altered by LHRH but she did respond normally to TttH. Her serum
prolactin level was measured, but unfortunately the result is
not recorded in her case records.
During twelve hours of water deprivation, her plasma
osmolarity rose above normal and she showed an inability to
concentrate her urine, indicating the need for combined therapy
with DDAVP in addition to corticosteroids. Oestrogen replacement
ojso
therapy Ibe required.
CASE VI - ME EDWARD BOYLE
HISTORY
Mr Boyle originally presented in 1970, at the age of 52, with
peristent frontal headaches of increasing frequency. lie was un¬
aware of any visual upset and his visual fields were not restricted.
X—ray examination showed expansion of the pituitary fossa and a
pituitary biopsy was performed via the trans-sphenoidal route,
confirming the presence of a chromophobe adenoma. In view of the
*
absence of signs of optic nerve compression he was treated with
radiotherapy.
SUBSEQUENT PRESENTATION AND INVESTIGATION
In April 1977 he was admitted to the Y/estern General Hospital
for reassessment on account of tiredness, mental slowness, poor
concentration, cold intolerance, constipation, impotence and loss
of libido. His shaving frequency had declined to once weekly,
whereas he had formerly shaved twice or thrice daily. He was on
no medications apart from antacids for a radiologically diagnosed
duodenal ulcer.
On examination, he was obese and mentally slow. His skin was
pale and soft and he had no pubic, axillary or body hair. Optic
fundi and visual fields were normal but it was noted that his knee
jerks showed delayed relaxation.
X-ray of his skull showed"considerable expansion of the
boundaries of the pituitary fossa by an intra-fossa mass."
Routine haematology was normal but serum electrolytes showed him
to have an elevated potassium level although his sodium
concentration was normal. Blood urea was slightly elevated and
his creatinine clearance was correspondingly low.
His plasma Cortisol levels were very low and showed no
diurnal variation but H5I, T^ resin uptake and free thyroxine
index were, surprisingly, within the normal range. A combined
pituitary function test was performed which evoked a normal
Cortisol response although growth hormone was unrecordable. LHRH
stimulation failed to produce a gonadotrophin response which
confirmed the clinical impression that he was gonadoti-ophin
deficient. The results of four hour radio iodine uptake studies
and the TRH stimulation test were not available and the decision
to commence thyroxine will depend on these results.
The x—ray appearance is suggestive of progression of the
tumour and his symptoms are too delayed to be a direct effect of
the radiotherapy. In addition to appropriate replacement therapy
more definitive treatment may be required, although unless signs
of visual field involvement develop, surgery will probably not be
necessary.
GENERAL DISCUSSION
ASSESSMENT OF PITUITARY FUNCTION
There are a number of factors which should be considered
when using hormone assays based on peripheral plasma and urine
samples to assess pituitary function.
These hormones are relatively unstable in blood at room
temperature. Thus the plasma must be separated and frozen as
quickly as possible. A good example is the plasma ACTII assay,
concerning which Dr J. G. Radcliffe of the Radioimmunoassay Unit,
Glasgow issues the following instruetions
1) At lease 10 mis of blood should be taken into a plastic
syringe and put into a cooled lieparinised plastic
container (e.g. in an ice bucket).
2) The sample must be centrifuged as soon as possible (within
20 minutes of sampling) in a refrigerated centrifuge (4°C).
3) The plasma (at least 5 ml) should be transferred to a
polystyrene tube and deep frozen (at least 20°C) immediately.
The time from sampling to deep freezing should be less than 45
minutes.
However, how often is this protocol vigorously followed in the
ward situation where blood samples may be left for up to two hours
or more before being centrifuged and then the plasma is slowly
frozen in the freezing compartment of the ward fridge. Such
sources of error are probably inevitable but should always be
considered when an unexpected result is obtained^ though it would
be helpful if the relative stabilities of the various hormones were
more widely appreciated.
The secretion of the pituitary hormones fluctuates
considerably over the course of a twenty four hour period. Growth
hormone and prolactin may be released in bursts during the resting
state and particularly in the early hours of sleep. Stress and
the fasting state of the individual have considerable influence on
their rate of secretion. Thus, a single plasma sample is unlikely
to reflect the overall output of these hormones and serial sampling
over the course of several hours is more representative. It is
unfortunate that methods for the estimation of these pituitary
hormones in urine are not readily available, for these would give
a good index of total daily output, providing that their renal
clearance was relatively constant.
Pituitary function can also be assessed in terms of the out¬
put of hormones from the target glands. Thus, in centres where
ACTH estimations are not readily available, the response of the
adrenal cortex in terms of plasma Cortisol or its excretory
products, urinary 17- hydroxycorticosteroids, is effectively used
to assay ACTH secretion, provided that there is no adrenal gland
pathology. Twenty four hour urinary 17- hydroxycorticosteroid
output is a good index of adrenal Cortisol secretion, so long as
certain drugs are withheld for twenty four hours before and during
the collection periods. These drugs include various antihyper¬
tensives, barbiturates, tranquillisers, diuretics and other drugs
which interfere with the assay. ACTH secretion characteristically
shows a diurnal variation over the twenty four hour period,
reaching a peak in the early morning and a trough in the late
evening. Loss of this diurnal variation in plasma ACTH or Cortisol
concentration may be the first sign of Cushing's disease. This
emphasises the point that, if it is intended to use single plasma
to
samples for diagnosis or^ compare patients and the effects of
therapy then they should be collected under as near identical
conditions as possible. (e.g. at 08°° hours before breakfast and
at midnight)
$
Gonadotropin.li secretion in women of reproductive age is
normally cyclical and can only be reliably interpreted in relation
to menstrual status. Thus weekly sampling is performed over a six
week period in the investigation of amenorrhoea or infertility and
the levels of the target ovarian hormones (i.e. ovarian steroids)
measured as well as gonadotrophins.
Suspected hyper or hyposecretion of pituitary hormones is
investigatedIfrf means of dynamic tests. If hyperfunction is
suspected, supressive tests which examine the negative feedback
control mechanism are employed, such as the use of dexamethasone
to inhibit ACT1I secretion and the administration of glucose to
suppress growth hormone secretion. The latter was used in the case
of Alexander Cook^as the absence of a fall in growth hormone level
is diagnostic of acromegaly.
If pituitary hypofunction is suspected the lesion may be
within the anterior pituitary itself or at hypothalamic level.
Administration of the appropriate hypothalamic releasing factor will
test the ability of the pituitary cells to release their hormone,
such as the use of TRI1 and LHRH in the combined pituitary function
test. Stimulation at the hypothalamic level may be achieved by
removing its negative feedback inhibition.
One example is the use of metyrapone which blocks the 11-|3
hydroxylase enzyme in the adrenal cortex, thus lowering circulating
Cortisol levels. This leads to stimulation of ACTII secretion by
removal of the inhibitory effect of Cortisol on the hypothalamus.
Administration of Clomiphene blocks oestrogen receptors in the
hypothalamus and thus reduces oestrogen feedback inhibition.
As well as being of considerable diagnostic value^such tests
have a vital role to play in the management of patients with
pituitary disease. For example, the failure of Andrew Cripp to
respond to LHRII indicated that he would not achieve puberty
spontaneously and would ultimately require therapy with gonado¬
tropins. Diane Gro-ham's inadequate response to Clomiphene may be
of therapeutic as well as of diagnostic value for it has shown
that this drug will not induce ovulation in her case.
Insulin hypoglycaemia is a particularly useful dynamic test
and before discussing its results in these six patients, I propose
to consider its physiological basis in some detail.
THE INSULIN I1YP0GLYCAEMIA TEST
The insulin hypoglycaemia test measures the response of the
hypothalamic - pituitary axis to the stress of hypoglycaemia.
Insulin is injected intravenously with the dose being adjusted
according to the subject's body weight. Half hourly samples of
blood are withdrawn through an indwelling cannula and assayed for
blood glucose, Cortisol and growth hormone. The stress is
considered adequate only if blood glucose falls below 2.2 mmol/l,
at which level there are associated systemic effects such as
sweating, pallor and tachycardia (Greenwood and Landon, 1966).
The test does not distinguish between pituitary and hypo¬
thalamic disorders as the stress is believed to act at the level
of the hypothalamus but it does give: an estimate of the ability
of the liypothalamo-pituitary axis to respond to stress.
An individual who has been hypophysectomised shows a marked
hypersensitivity to the hypoglycaemic action of exogenous insulin
with a profound fall in blood glucose and a slow return to the
base line levels. This insulin hypersensitivity is also seen after
a meal rich in carbohydrate, when secondary hypoglycaemia occurs
following clearance of the glucose load from the blood. It is most
important that any individual who is suspected of having deficient
pituitary reserve is very carefully supervised during the course
of an insulin hypoglycaemia test, or the profound prolonged hypo-
glycaemia may lead to coma or convulsions. Thus it is common
practice to give a smaller dose of insulin (0.1 mg/kg rather than
0.15 mg/kg) when pituitary deficiency is suspected.
It is interesting to consider the basis of this insulin hyper¬
sensitivity which is usually assumed to be due to the absence of
ACTII and corticosteroids.
Insulin appears to be the only hormone responsible for lower¬
ing the blood glucose level, while several hormones act in
different ways to counteract the effects of insulin and raise blood
glucose levels. Insulin is thought to act by enhancing the uptake
of glucose by peripheral tissues and by the hepatic cells in
which it is stored as glycogen.
As blood sugar levels fall in the fasting state there is
rapid secretion of adrenaline and glucagon which both activate
the hepatic enzyme glycogen phosphorylase, leading to release of
stored glucose. This mechanism, which counteracts hypoglycaemia,
is backed up by the release of growth hormone and ACTH. Growth
hormone appears to inhibit glucose uptake by peripheral tissues
while enhancing the mobilisation of free fatty acids from adipose
tissue which acts as an alternative metabolic substrate. It also
acts on hepatic cells and promotes glucose release.
Adrenal glucocorticoids, under the control of ACTH from the
anterior pituitary, also decrease peripheral glucose utilisation,
while enhancing glucose production from non-carbohydrate pre¬
cursors through glue one ogenetic. pathways. They also promote
hepatic glycogen deposition, thereby ensuring that, during pro¬
longed stress, these reserves are not exhausted. Glucocorticoids
also facilitate and enhance the hyperglycaeraic effects of both
glucagon and adrenaline. (Ramey and Goldstein, 1957)
It is not established which, if any sipgle one, of these
hyperglycaemic agents is predominantly responsible for the rapid
return to euglycaemia after insulin administration in normal
subjects and why insulin hypersensitivity follows liypophysectomy.
However current opinion considers that the loss of either growth
hormone (Altszuler, 1974) or adrenaline (V/urtman et nl, 1972) is
responsible for this latter phenomenon. However, both glucagon
and adrenaline are powerful hyperglycaemic agents and at first
sight one would not expect them to be influenced by hypophysectomy.
De Bodo and Altzuler (1958) in a detailed review of the
subject compared the effects of insulin in hypophysectomised dogs
with those which had been adrenalectomised. At doses of insulin
between 0.08 and 0.25 mg/kg, both sets of dogs were hypersensitive
to insulin. However, using a small dose of insulin (0.025 mg /kg)
the adrenalectomised dogs responded with spontaneous return to
normoglycaeraia, while the hypophysectomised dogs were still insulin
hypersensitive. Furthermore they showed that in the absence of
corticosteroids, there was failure of both adrenaline and glucagon
to raise blood glucose levels due to an impairment of their action
at hepatic level. They were able to abolish the insulin hyper¬
sensitivity of hypophysectomised animals by administration of
maintenance doses of growth hormone. These observations have been
supported by later workers and Altszuler (1974) concludes that the
insulin hypersensitivity seen after hypophysectomy is due to the
loss of growth hormone as well as ACTII.
However Wurtman and Pohorecky (1972) have a very different
explanation which they often quote as an introduction to their
work on the corticosteroid dependence of the adrenal noradrenaline
methylating enzyme. They have good evidence that phenylethanolainine
-N-methyl transferase (P.N.M.T.), the enzyme which catalyses the
N-methylation of noradrenaline to produce adrenaline, is dependent
for its action on the presence of adrenal glucocorticoids.
Anatomically the venous drainage of the cortex passes through the
medulla, bathing its cells with blood containing an extremely high
concentration of glucocorticoids (one hundred fold greater than
that present in the general circulation). Hypophysectomised dogs
have adrenal cortical atrophy and have been shown to have low
acitivty of PNMT and low outputs of adrenaline. Maintenance doses
of corticosteroids do not result in the return of this enzyme's
activity as the blood bathing the medulla will merely contain
systemic levels of these steroids. Only massive systemic doses
of corticosteroids give a sufficient intra-adrenal concentration
to result in an increase in the activity of PNMT.
In their review, Wurtraan et al postulate that it is the
absence of adrenaline that is responsible for insulin hyper¬
sensitivity as only this hormone coulcl be released and act quickly
enough to explain the rapid return to normoglycaemia seen in the
noxrnal subject. They do not regard the role of growth hormone to
be important, claiming that its release and action would be too
slow. They never mention glucagon which lias been shown to have
both a rapid release and a rapid blood glucose mobilising effect.
(Sawin, 1969) Furthermore they do not discuss the dependence of













































for their hyperglycaemic action.
More evidence is required before these arguments can be
resolved. It would be interesting to examine in more detail
the response to insulin of hypophysectomised patients who are
kept on their maintenance steroid dose and thus should have
normal peripheral responses to adrenaline and glucagon.
I shall now consider the findings of the insulin hypo-
glycaemia test in the six cases presented above. Their results,
as compared with those of six controls, are plotted graphically.
Andrew Crisp experienced a profound, prolonged hypoglyeueraic
response to insulin, with no rise in either plasma Cortisol or
growth hormone levels and will probably need steroid replacement
therapy for life. Elizabeth Aitken, whose basal plasma Cortisol
levels were low with a loss of the normal diurnal variation,
failed to produce a Cortisol response to an adequate fall in her
blood glucose level. However she did have a prompt, albeit sub¬
normal, growth hormone response and returned spontaneously to
euglycaemia, which supports the view that growth hormone is very
important in counteracting the hypoglycaeraic action of insulin.
Marion Stark was slow to return to normoglycaemia and
exhibited a markedly impaired growth hormone response although
her plasma corticol response at one hour was adequate. However
her basal plasma Cortisol levels were low, but showed a normal
diurnal variation and as her pituitary appeared to respond
adequately to stress, steroid replacement therapy was withheld.
Once again the glucose and growth hormone responses seem to be
related. Edward Boyle had unrecordable diurnal plasma Cortisol
levels but showed a normal Cortisol response to insulin hypo-
glycaemia. This emphasises the importance of using dynamic tests
of pituitary function, rather than relying on estimations of the
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